Surface Protein gp120 - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Surface Protein gp120 - Pipeline Review, H2 2016

Surface Protein gp120 - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Surface Protein gp120 - Pipeline Review, H2 2016
Published Aug 31, 2016
75 pages — Published Aug 31, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Surface Protein gp120 - Pipeline Review, H2 2016, provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics.

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120
- The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects
- The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Surface Protein gp120
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and a

  
Source:
Document ID
GMDHC0508TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables61
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Surface Protein gp120 Overview81
Therapeutics Development93
  Surface Protein gp120 Products under Development by Stage of Development91
  Surface Protein gp120 Products under Development by Therapy Area101
  Surface Protein gp120 Products under Development by Indication111
Surface Protein gp120 Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Surface Protein gp120 Products under Development by Companies142
Surface Protein gp120 Products under Development by Universities/Institutes162
Surface Protein gp120 Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Surface Protein gp120 Companies Involved in Therapeutics Development246
  GlaxoSmithKline Plc241
  Osel, Inc.251
  Sanofi Pasteur SA261
  TeneoBio Inc271
  United Biomedical, Inc.281
  ViiV Healthcare Limited291
Surface Protein gp120 Drug Profiles3029
  Abzentek Drug Profile301
  AIDSVAX B/B + ALVAC-HIV vCP1521 Drug Profile312
  Biologic for Infectious Disease Drug Profile332
  BMD-101 Drug Profile351
  BMD-104 Drug Profile361
  BMS-585248 Drug Profile371
  DS-003 Drug Profile381
  fostemsavir tromethamine Drug Profile393
  HIV [strains C1086 + TV1] (bivalent) vaccine Drug Profile421
  HIV vaccine Drug Profile431
  HIV vaccine Drug Profile441
  HIV vaccine 1 Drug Profile451
  HIV-1 vaccine Drug Profile461
  HNG-156 Drug Profile471
  M-48U1 Drug Profile481
  Monoclonal Antibodies to Inhibit GP120 for HIV Drug Profile491
  Monoclonal Antibodies to Inhibit Gp120 for HIV-1 Infection Drug Profile501
  Monoclonal Antibodies to Target GP120 and GP41 for HIV Drug Profile511
  Monoclonal Antibody to Inhibit Glycoprotein 120 for HIV Drug Profile521
  Recombinant Peptide to Inhibit gp120 for HIV-1 Drug Profile531
  Recombinant Protein to Target gp120 for HIV-1 Infections Drug Profile541
  Small Molecules to Target GP120 and Gp41 for HIV-1 Infections Drug Profile551
  Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection Drug Profile561
  VCP-2438 Drug Profile571
  VRC-01LS Drug Profile581
Surface Protein gp120 Dormant Projects593
Surface Protein gp120 Discontinued Products621
Surface Protein gp120 Featured News &Press Releases6311
  May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa631
  Jan 07, 2016: National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology641
  Dec 02, 2015: Abzyme Research Foundation's Inaugural ENDHIV BALL Launches $3 Million Fund for New Therapeutic HIV Vaccine Trial641
  Jul 21, 2015: Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients651
  Jul 08, 2015: Scripps research-designed drug candidate significantly reduces HIV reactivation rate661
  Feb 25, 2015: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation671
  Oct 03, 2014: Bristol-Myers Squibb Presents Data of BMS-663068 at IDWeek 2014 Showcasing Continued Innovation in Virology681
  Jul 30, 2014: Dissolvable fabric loaded with medicine might offer faster protection against HIV691
  Mar 05, 2014: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients701
  May 06, 2013: Duke Researchers Report Additional Information From Phase III HIV Vaccine Trial In Thailand711
  Dec 06, 2012: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission722
Appendix742
  Methodology741
  Coverage741
  Secondary Research741
  Primary Research741
  Expert Panel Validation741
  Contact Us741
  Disclaimer751

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Surface Protein gp120 - Pipeline Review, H2 2016" Aug 31, 2016. Alacra Store. May 11, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Surface-Protein-gp120-Pipeline-Review-H2-2016-2088-16528>
  
APA:
Global Markets Direct - Market Research. (2016). Surface Protein gp120 - Pipeline Review, H2 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved May 11, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Surface-Protein-gp120-Pipeline-Review-H2-2016-2088-16528>
  
US$ 3,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.